Signalpoint

← Full daily brief

Mass Tort brief

Abbott's Formula Settlement, Bellwether Shifts, and Key Mass Tort Rulings

Major settlements in formula and adult platform litigation accompany key appellate rulings in real estate and drug price-fixing.

Signalpoint TeamBrief

Mass Tort

Abbott agreed to a $670 million settlement — eliminating a massive Missouri verdict to cap appellate risk while fighting remaining infant formula claims.

BackgroundParents sued formula manufacturers alleging specialized infant formulas like Similac carried undisclosed risks of necrotizing enterocolitis for premature babies. Abbott maintained that its products are safe and that the agreement contains no admission of liability.

Points
  1. The agreement resolves the Missouri Gill verdict which faced interest accruals pushing potential financial exposure near $600 million.
  2. Roughly 1,700 lawsuits covering about 12,700 infants remain pending across federal multidistrict litigation and state court dockets, preserving trial risk.
  3. Abbott chose the bulk deal to eliminate interest accruals and appellate risk from the Missouri verdict while continuing to defend against remaining state claims.
SourcesWall Street Journal: Abbott to Pay $670 Million to Settle Baby-Formula Litigation (opens in new tab)Insurance Journal: Abbott Agrees to $670 Million Settlement of Infant Formula Cases (opens in new tab)

Mass Tort

A second bellwether plaintiff dropped her youth addiction suit without a payout — depriving plaintiffs of leverage ahead of major social media trials.

BackgroundMass tort litigation consolidated in California state court and federal multidistrict dockets alleges social media algorithms were engineered to induce youth addiction. Bellwether trials serve as key tests for establishing jury valuation and settlement leverage across thousands of consolidated claims.

Points
  1. This marks the second bellwether plaintiff to walk away without a financial payout shortly before trial this summer, weakening plaintiffs' trial momentum.
  2. Co-defendant TikTok previously settled claims with the plaintiff privately prior to her voluntary dismissal of the remaining tech platforms.
  3. Over 3,300 youth addiction claims remain consolidated across California state court and federal multidistrict dockets, keeping tech firms exposed to future trial dates.
SourcesThe Next Web: New Jersey teen drops claims against Meta, Google, and Snap weeks before trial (opens in new tab)Benzinga: Teen Drops Landmark Social Media Addiction Lawsuit Against Meta, Google and Snap Ahead of October Trial (opens in new tab)

Mass Tort

An appeals court upheld the $1 billion real estate antitrust settlement — permanently dismantling mandatory buyer-broker commission rules across national markets.

BackgroundHomeowners sued the National Association of Realtors and major brokerages, alleging rules requiring sellers to pay buyer-broker commissions artificially inflated real estate transaction fees nationwide. The ruling resolves major antitrust challenges to traditional real estate fee structures.

Points
  1. The appellate decision rejected appeals brought by seven separate groups of objectors and intervenors, clearing the final legal hurdle to execution.
  2. The ruling formally cements the elimination of mandatory cooperative commission rules across Multiple Listing Services nationwide, fundamentally changing home buying.
  3. Real estate brokerages must now negotiate buyer representation commissions independently from property listings, lowering structural friction for home sales.
SourcesDuane Morris Blogs: Eighth Circuit Affirms Landmark Billion Dollar Class Action Settlement In Real Estate Broker Commission Antitrust Litigation (opens in new tab)

Mass Tort

A federal court rejected drug makers' damages limits — keeping generic manufacturers facing full financial liability in Humana's price-fixing trial.

BackgroundHealth insurers sued generic pharmaceutical manufacturers alleging widespread price-fixing conspiracies across generic drug markets. Drug makers sought to reduce potential damages based on separate insurer settlements and indirect purchasing calculations.

Points
  1. Generic manufacturers sought a 50.8% reduction in Humana's indirect volume of commerce calculations, which the court rejected entirely.
  2. The court rejected defense demands for a $360 million damages set-off based on Humana's separate private settlement with Walgreens.
  3. The ruling clears the way for trial proceedings evaluating full generic drug price-fixing liability without artificially capped damages.
SourcesVitalLaw: ANTITRUST—E.D. Pa.: Generic drug manufacturers denied damages motion in price-fixing case (opens in new tab)

Mass Tort

Mass Tort

Unlock the full brief

Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.

Or read free in the appDownload on the App Store